Literature DB >> 24502877

Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials.

Gianluigi Savarese1, Alessandra Dei Cas2, Giuseppe Rosano3, Carmen D'Amore1, Francesca Musella1, Susanna Mosca1, Martin F Reiner4, Roberto Marchioli5, Bruno Trimarco1, Pasquale Perrone-Filardi6.   

Abstract

BACKGROUND: The association between renal dysfunction and risk of cardiovascular (CV) events and mortality has been reported in several studies. However, it is unclear whether reduction in urinary albumin excretion (UAE) is associated with reduced risk of clinical events. Therefore, we sought to investigate, in a meta-regression analysis of randomized studies enrolling hypertensive and/or diabetic patients, whether changes in UAE are associated with changes in CV outcomes and all-cause mortality.
METHODS: MEDLINE, ISI Web of Science, Cochrane Database and Scopus were searched for randomized trials enrolling more than 200 diabetic and/or hypertensive patients, reporting UAE at baseline and at end of follow-up and CV events [CV death, myocardial infarction (MI), and stroke], as well all-cause mortality.
RESULTS: Thirty-two trials enrolling 80,812 participants were included in analyses. Meta-regression analysis showed that each 10% reduction of UAE was significantly associated with 13% reduction of MI (Regression Coefficient [RC]:0.0055; 95% Confidence Interval [CI]:0.0014 to 0.0095; p=0.010), with 29% reduction of stroke (RC:0.0124; CI:0.0030 to 0.0218; p=0.013) and with 14% reduction of the composite outcome (CV death, MI, stroke)(RC:0.0059; CI:0.0027 to 0.0090; p=0.001), whereas not significantly associated with all-cause (RC:0.0028; CI:-0.0047 to 0.0103; p=0.486) and CV mortality (RC:0.0028; CI:-0.0047 to 0.0103; p=0.447). Results were mostly confirmed by sensitivity analysis. No heterogeneity or publication bias was detected.
CONCLUSIONS: Reduction in UAE is associated with reduced risk of MI and stroke in diabetic and/or hypertensive patients. These findings suggest that UAE changes may represent a valuable intermediate end-point for CV risk evaluation in clinical practice.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular events; Cardiovascular risk; Urinary albumin excretion

Mesh:

Substances:

Year:  2014        PMID: 24502877     DOI: 10.1016/j.ijcard.2014.01.065

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

Review 1.  Microalbuminuria in primary hypertension: a guide to optimal patient management?

Authors:  Francesca Viazzi; Francesca Cappadona; Roberto Pontremoli
Journal:  J Nephrol       Date:  2016-07-14       Impact factor: 3.902

Review 2.  Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetes.

Authors:  Francesca Viazzi; Barbara Bonino; Elena Ratto; Salvatore De Cosmo; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-08-01

3.  Proteinuria and risk of stroke in patients with hypertension: The Kailuan cohort study.

Authors:  Anxin Wang; Liye Dai; Zhaoping Su; Shuohua Chen; Junjuan Li; Shouling Wu; Yongjun Wang; Yilong Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-06       Impact factor: 3.738

4.  Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

Authors:  Rajiv Agarwal; Patrick Rossignol; Dahlia Garza; Martha R Mayo; Suzette Warren; Susan Arthur; Alain Romero; William B White; Bryan Williams
Journal:  Am J Nephrol       Date:  2018-09-03       Impact factor: 3.754

Review 5.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

6.  Chronic kidney disease as a predictor of clinical risk in the elderly.

Authors:  Francesca Viazzi; Francesca Cappadona; Barbara Bonino; Roberto Pontremoli
Journal:  J Geriatr Cardiol       Date:  2016-03       Impact factor: 3.327

7.  Changes in Proteinuria on the Risk of All-Cause Mortality in People with Diabetes or Prediabetes: A Prospective Cohort Study.

Authors:  Yang Sun; Anxin Wang; Xiaoxue Liu; Zhaoping Su; Junjuan Li; Yanxia Luo; Shuohua Chen; Jianli Wang; Xia Li; Zhan Zhao; Huiping Zhu; Shouling Wu; Xiuhua Guo
Journal:  J Diabetes Res       Date:  2017-09-27       Impact factor: 4.011

8.  Changes in proteinuria and the risk of myocardial infarction in people with diabetes or pre-diabetes: a prospective cohort study.

Authors:  Anxin Wang; Yang Sun; Xiaoxue Liu; Zhaoping Su; Junjuan Li; Yanxia Luo; Shuohua Chen; Jianli Wang; Xia Li; Zhan Zhao; Huiping Zhu; Shouling Wu; Xiuhua Guo
Journal:  Cardiovasc Diabetol       Date:  2017-08-15       Impact factor: 9.951

Review 9.  Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale.

Authors:  Michele Provenzano; Giuseppe Coppolino; Luca De Nicola; Raffaele Serra; Carlo Garofalo; Michele Andreucci; Davide Bolignano
Journal:  Front Cell Dev Biol       Date:  2019-12-03

10.  Association of Persistent, Incident, and Remittent Proteinuria With Stroke Risk in Patients With Diabetes Mellitus or Prediabetes Mellitus.

Authors:  Anxin Wang; Ruixuan Jiang; Zhaoping Su; Jia Zhang; Xingquan Zhao; Shouling Wu; Xiuhua Guo
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.